An Overview of Basic IRB Regulations

Ada Sue Selwitz, M.A.
Director, Office of Research Integrity
Adjunct Associate Professor, Department
of Behavioral Science, College of Medicine
Co-Director Bioethics and Research Integrity Core,
Center for Clinical and Translational Sciences
University of Kentucky

Disclaimer
Views Expressed in This Presentation are Those of the Speaker and Not Necessarily of the University of Kentucky

Compliance Oversight
• OHRP Compliance Oversight Activities: Significant Findings and Concerns of Noncompliance
  http://www.hhs.gov/ohrp/compliance/findings.pdf
• 2008: 33 OHRP Determination Letters
Objective

To Provide an Overview of Basic IRB Regulations

Layers of Regulations

- International
- Federal
- Sponsor
- State
- Local

Overview: Federal Requirements

- Regulatory Framework
- Applicability
- Authority
- Membership
- Mechanisms of Review
- Types of Review
- Criteria for Approval Including Informed Consent & Waiver
- Reporting
- Recordkeeping
Regulatory Framework
Which Agencies Have Issued Regulations Impacting Human Research Protection?

Federal Policy
"Common Rule"

- Effective August 19, 1991
- Adopted by 19 Federal Agencies
- Based on Subpart A 45 CFR 46

Common Rule Agencies

- 7 CFR 1c Agric
- 10 CFR 745 DOE
- 14 CFR 1230 NASA
- 15 CFR 27 Commerce
- 16 CFR 1028 CPSC
- 24 CFR 60 HUD
- 28 CFR 46 DOJ
- 32 CFR 219 DOD
- 34 CFR 97 Education
- 38 CFR 18 VA
- 45 CFR 46 HHS
- 45 CFR 690 NSF
- 49 CFR 11 DOT
- 40 CFR 26 EPA
- 22 CFR 225 AID
- Policy
- PL 108-458 DHS
- PL 103-206 SSA
- EO 12333 CIA
DHHS 45 CFR 46

- Subpart A - Core Requirements
- Subpart B - Pregnant Women, Human Fetuses, and Neonates
- Subpart C - Prisoners
- Subpart D - Children

Food and Drug Administration (FDA) Regulations

- 21 CFR 50 - Protection of Human Subjects*
- 21 CFR 56 - Institutional Review Boards
- 21 CFR 54 - Financial Disclosure by Clinical Invest.
- 21 CFR 312 - Investigational New Drug
- 21 CFR 314 - New Drug Application
- 21 CFR 320 - Bioavailability and Bioequivalence
- 21 CFR 211 - Manufacturing
- 21 CFR 600 - Biologics
- 21 CFR 812; 814 - Devices

*Includes Subpart on Children

Examples of Auxiliary Laws

- Dept of Education
  - 34 CFR 97 Subpart D
  - 34 CFR 98
  - 34 CFR 99
  - 34 CFR 360.4(g)
  - 34 CFR 366, 3.3

- Dept of Justice
  - 28 CFR 912 Subpart B

- Dept of Energy
  - Order 401.1
  - Order 451.4A
  - 10 CFR Part 100

- Dept of Defense
  - 10 USC 980
  - DoD 5119.2
  - DoD 5000.8
  - DoD 5002.2
  - AFIP 40-402
  - AFIP 49-005
  - AR 70-25
  - AR 45-39
  - SECNAVINST 5000.36B
  - NAVEDINST 5000.2
  - RUMERTINST 0500.12
  - INSTTRTRINST 0500.41A
  - USBHC Instruction 3201

Jeff Cooper, IRB 201
Which of the Agencies Have Subparts?

- 45 CFR 46 & Homeland Security
  - B: Pregnant Women, Fetuses, & Neonates
  - C: Prisoners
  - D: Children
- FDA
  - D: Children
- U.S. Department of Education
  - D: Children

Federal Regulations: Children

<table>
<thead>
<tr>
<th>Category</th>
<th>Requirements</th>
</tr>
</thead>
<tbody>
<tr>
<td>1) Minimal Risk</td>
<td>• Parental Permission</td>
</tr>
<tr>
<td></td>
<td>• Child's Assent</td>
</tr>
<tr>
<td>2) Greater Than Minimal Risk, Direct Benefit</td>
<td>• Risk Justified By Benefit</td>
</tr>
<tr>
<td></td>
<td>• Risk/Benefit is as Favorable as the Alternative</td>
</tr>
<tr>
<td></td>
<td>• Parental Permission</td>
</tr>
<tr>
<td></td>
<td>• Child's Assent as Required By IRB</td>
</tr>
</tbody>
</table>

Helen McGough

Federal Regulations: Children

<table>
<thead>
<tr>
<th>Category</th>
<th>Requirements</th>
</tr>
</thead>
<tbody>
<tr>
<td>3) Greater Than Minimal Risk/ No Direct Benefit/ Yield Generalizable Knowledge</td>
<td>• Minor Increase Over Minimal</td>
</tr>
<tr>
<td></td>
<td>• Experiences Commensurate With Inherent, Actual or Expected Situations</td>
</tr>
<tr>
<td></td>
<td>• Research Expected to Yield Knowledge of Vital Importance</td>
</tr>
<tr>
<td></td>
<td>• Both Parents Permission Obtained</td>
</tr>
<tr>
<td></td>
<td>• Child Assents</td>
</tr>
</tbody>
</table>

Helen McGough
Federal Regulations: Children

<table>
<thead>
<tr>
<th>Category</th>
<th>Requirements</th>
</tr>
</thead>
<tbody>
<tr>
<td>4) Otherwise Not Approvable/Opportunity to Understand, Prevent or Alleviate Serious Problem Affecting Children</td>
<td>HHS Consultation of Experts</td>
</tr>
<tr>
<td></td>
<td>Public Comment</td>
</tr>
</tbody>
</table>

Helen McGough

Example: Auxiliary Requirements

- Confidentiality Certificates DHHS
  http://www.hhs.gov/ohrp/humansubjects/guidance/certconf.pdf

- Family Educational Rights and Privacy Act (FERPA)
  http://www.ed.gov/offices/OII/fpco/ferpa

- Protection of Pupil Rights Amendment (PPRA) [No Child Left Behind]
  http://www.ed.gov/offices/OII/fpco/ppra

Example: Auxiliary Requirements

- Draft Guidance for Humanitarian Device Exemption Holders, Institutional Review Boards, Clinical Investigators, and FDA Staff - HDE Regulation: Questions and Answers

  August 5, 2008

  http://www.fda.gov/cdrh/ode/guidance/1668.html
Recent Federal Changes

- UK Office of Research Integrity: Selected Recent Changes at the Federal Level Impacting IRBs

(Signature and Information Provided)

Focus Today On:

- DHHS 45 CFR 46 Subpart A Common Rule
- FDA 21 CFR 50 Informed Consent
- FDA 21 CFR 56 IRB

Which regulations apply?

- FDA: Research Involves Products Regulated By FDA
- Common Rule: Federally Supported or Conducted or Conducted in an Institution that Agrees to Review All Research Under the Common Rule
- Both: If Federally Funded Research Involves a FDA Regulated Product or FDA Regulated Research is Conducted in an Institution that Agrees to Review All Research Under the Common Rule
- Subparts: If Research is Funded by NIH or Other Federal Agency that Has Adopted Some or All Subparts

*Assurance/Policy: Helen McGough
Is This Research With Human Subjects?

- I want to interview holocaust survivors for a book I am writing.
- I'm only looking at records that are linked to an code, but no actual name.
- I'm only using pathology tissue from a deceased individual?
- I'm just a psychology student doing a project for my course.
- This is a QI initiative but I may want to publish it.
- I just want to review billing information.
- I'm just performing an innovative procedure.
- I am trying to compare two methods of teaching to better educate students.
- I am doing field observation for a book I am writing about Africa.

---

How Do You Decide What Needs IRB Review?
Common Rule/45 CFR 46

1. Do Activities Meet the Federal Definition of “Research”? And

2. Do Activities Meet the Federal Definition of “Human Subjects”? 

---

“Research”*

A Systematic Investigation Designed to Develop or Contribute to Generalizable Knowledge

*45 CFR 46 & Common Rule
"Human Subject"*
A Living Individual About Whom an Investigator... Conducting Research Obtains (1) Data Through Intervention or Interaction With the Individual, or (2) Identifiable Private Information

*Common Rule/45 CFR 46.102(f)

Is This Research With Human Subjects?
- I want to interview holocaust survivors for a book I am writing
- I'm only looking at records that are linked to an code, but no actual name.
- I'm only using pathology tissue from a deceased individual?
- I'm just a psychology student doing a project for my course.
- This is a QI initiative but I may want to publish it
- I just want to review billing information
- I'm just performing an innovative procedure
- I am trying to compare two methods of teaching to better educate students
- I am doing field observation for a book I am writing about Africa

Susan Konetzky, Children's Hospital Boston

The Case of the Missing Person
- A Resident is Very Interested in Child Abuse and Believes that it is Under-Reported Even Though There are Mandatory Reporting Laws.
- The Resident Pulls Emergency Room Records for the Past Year for All Child Health-Related Visits.
- To Raise Awareness, the Resident Writes an Article Describing the Data and the Lack of Documented Referrals to Police/Child Protective Services.

@ Gary L. Chadwick
The Case of the Missing Person

- Who is the 'Subject'?
  - the Kids?
  - the Parents?
  - the Health Care Providers?
  - None of the Above?
  - All of the Above?

@ Gary L. Chadwick

Helpful OHRP Guidance Documents

- Guidance on Research Involving Coded Private Information or Biological Specimens – October 16, 2008

- OHRP Human Subject Regulations Decision Charts
  http://www.hhs.gov/ohrp/humansubjects/guidance/decisioncharts.htm

  http://www.hhs.gov/ohrp/humansubjects/guidance/engage08.html (Use to Determine if an Assurance is Needed)

How Do You Decide What Needs IRB Review?

- Stepwise Process:
  First Common Rule/45 CFR 46
  Next: FDA 21 CFR 56
FDA
1. Do Activities Involve Use of Regulated Products (Drugs, Devices, Biologics, Food/Color Additives)?
2. Do Activities Involve Clinical Investigation? And
3. Do Activities Meet FDA Drug Definition of Human Subjects? Or Do Activities Meet FDA Device Definition of Human Subjects?

"Clinical Investigations"
• A Clinical Investigation Means Any Experiment That Involves a Test Article (e.g., Drug, Device, Biologics) and One or More Human Subjects

*FDA 21 CFR 56.102

"Human Subjects" -
Drug, Food, Biologic

"An Individual Who is or Becomes a Participant in Research Either As a Recipient of a Test Article or As a Control. A Subject May Be Either a Healthy Human or a Patient"

*FDA 21 CFR 56.102(e)
**Human Subjects** - Medical Devices

"A Human Who Participates In an Investigation, Either As an Individual on Whom or on Whose Specimen an Investigational Device is Used or Who Participates As a Control. A Subject May Be in Normal Health or May Have a Medical Condition or Disease"

*FDA 21 CFR 812.3(p)*

---

**What Do You Do When...?**

It is 5:00 PM on Friday. Physician Calls. He Has a Patient Who is Critically Ill. Wants to Administer an Investigational Drug Immediately Without Prior IRB Review.

---

**FDA "Emergency Use" – Single Patient**

Prior IRB Review Not Required:

- Use of a Test Article on a Human Subject in a Life-Threatening Situation
- In Which No Standard Acceptable Treatment is Available
- In Which There is Not Sufficient Time to Obtain IRB Approval

*21 CFR 60.102(d) – Not In 45 CFR 46*
"Emergency Use" of Test Article

- "Emergency Use" Must be Reported to IRB Within 5 Working Days
- Any Subsequent Use of the Test Article at the Institution is Subject to IRB Review

Authority of IRB*

- Approve, Disapprove, or Modify
- Conduct Continuing Review
- Observe / Verify Changes
- Suspend or Terminate Approval

*Common Rule/45 CFR 46/FDA

IRB Membership

- At Least 5 Members
- Both Genders, If Possible
- Varied Professions
- Member with Nonscientific Concern
- Member with Scientific Concern
- Member Not Otherwise Affiliated with the Institution
IRB Membership
- Experience and Expertise
- Diversity of Backgrounds
- Sensitivity to Community Attitudes
- Knowledge of Institutional Commitments and Regulations, Applicable Law, Standards of Professional Conduct
- Knowledgeable & Experienced with Vulnerable Subjects
- Special Competencies of Ad Hoc Consultants

Mechanisms for Review
- Exemption*
- Expedited Review
- Full Review (Convened)

*FDA Regulations Differ From the 45 CFR 46 and Common Rule

Exemptions
45 CFR 46 & Common Rule*
- Six Categories/Exempt
- Determination Does Not Have to Be Made By the IRB But Should Not Be Made By the PI

*FDA Has Adopted Only One Exemption
6 Categories of Exempt Research
45 CFR 46.101(b)

1. Educational Settings*
2. Tests, Surveys, Observation*
3. Public Officials/Federal Statute*
4. Existing Data, Documents, Specimens*
5. Federally Funded Demonstration Projects*
6. Taste, Food Quality, Consumer Tests

*Do Not Apply to FDA Regulated Research

Investigator Plans to Send Mail Questionnaire to All Patients Who Are Seen By the Cancer Center to Assess Their Satisfaction With Quality of Innovative Services that are Being Offered at the Center. The Investigator Plans to Include Data in Article She is Planning to Write on the Center's New Innovative Approach to Patient Care. Prospective Subjects Will Be Asked to Complete Survey Without Including Any Identifiers and Return in Self-Addressed Return Envelope. No Identifying Information Will Be Collected. No Follow-Up Contact is Planned.

Is the Study Eligible for Exemption?
Ada Sue Selwitz, University of Kentucky

Exemption category 2: Tests, Surveys, Interviews, Observation

- Research Involving the Use of Educational Tests (Cognitive, Diagnostic, Aptitude, Achievement), Survey Procedures, Interview Procedures or Observation of Public Behavior Unless

NOTE: 4 Broad Categories!
Exemption Category 2:
Exceptions

1. Information Obtained is Recorded in Such a Manner That Human Subjects Can Be Identified, Directly or Through Identifiers Linked to the Subjects; AND

2. Any Disclosure of the Human Subjects' Responses Outside the Research Could Reasonably Place the Subjects at Risk of Criminal or Civil Liability or Be Damaging to the Subjects' Financial Standing, Employability, or Reputation

Exemptions: Category 4

Collection or Study of Existing Data, Documents, Records, Pathological Specimens or Diagnostic Specimens If Publicly Available or Recorded Without Identifiers

Expedited Review

• Designated IRB Reviewer
• Reviewer May Not Disapprove
• Meets Expedited Review Criteria
• Meets 45 CFR 46.111 Criteria
• Members Informed
Expedited Review Criteria

- No More than "Minimal Risk"
  And
- Falls in One or More Federally Specified Categories
- Minor Change in Previously Approved Research

"Minimal Risk"
The Probability and Magnitude of Harm or Discomfort Anticipated in the Research are Not Greater In and Of Themselves From Those Ordinarily Encountered in Daily Life or During the Performance of Routine Physical or Psychological Examination or Tests.

- What Are the Chances of Harm and Are They Greater Than Ordinary Daily Life?
- What Magnitude of Harm? Is It Greater Than Ordinary Daily Life?
- Whose Daily Life?
Eligible for Expedited Review:
(Initial Review)

- Clinical Studies:
  IND/IDE NOT Required
- Blood Sample Collection (Routine Methods—Small Amounts)
- Prospective Collection of Biological Samples—Noninvasive Means
- Data Collected Through Noninvasive Means
  (Routinely Practiced in Clinical Settings)

- Materials (Data, Documents, Specimens etc.) Have Been Collected or Will Be Collected for Non-Research Purposes
- Collection of Voice, Video or Digital Data for Research Purposes
- Individual or Group Behavior, Surveys, Interviews, Oral Histories

[Signature]
Susan Kornskey, Children's Hospital

Eligible for Expedited Review:
(Continuing Review)

- Continuing Review of Research: A) Closed to Enrollment, Interventions Completed, Active Only for Long-Term Follow-Up; B) No Subjects Enrolled & No Additional Risk; C) Limited to Data Analysis
- Continuing Review of Minimal Risk Research (Not Under IND or IDE) Where No Additional Risks Have Been Identified

Expedited Review

- "Minor Change in Previously Approved Research"
- What is a "Minor Change"?
Caution for IRBs: Expedited Procedures

- IRBs Need to Develop Mechanism to Keep All Members Advised of Research Which Has Been Approved by Expedited Review
- Expedited Does Not Mean Cursory, Documentation of Substantive Review is Essential
- Err on the Side of Full Review, if Any Question
- Expedited Review is an Option
- Many Methods to Conduct Expedited Review

Susan Kometsky, Children's Hospital

Full Review Requirements

- Conducted at Convened Meeting
- Quorum Present
- Nonscientific Representative*
- 45 CFR 46.111 Satisfied
- Approval by Majority of the Quorum
- Conflict of Interest Abstain from Vote/Leave Room
- PI Informed of Outcome in Writing

*If FDA, Physician Representative

Approved By the Majority

- # Voting Members Present
  - 14
- Vote: 7 For; 6 Against;
  - 1 Abstain
- Was the Study Approved?

Ada Sue Selzitz, University of Kentucky
When Does the Full IRB Need to Review a PI Response?

- When the IRB Requests Substantive Modifications or is Information Seeking, IRB Approval Must Be Deferred, Pending Subsequent Review By the Full IRB
- The IRB Must Stipulate Specific Revisions to Allow a Designated Reviewer to Later Approve the Research on Behalf of the IRB, (Simple Concurrence)

Types of Review

- Initial Review
- Continuation Review
- Amendment Review
- Adverse Effect/Unanticipated Problem
- Noncompliance

Types of Review: Continuing Review

An IRB Shall Conduct Continuing Review at Intervals Appropriate to the Degree of Risk, But Not Less Than Once Per Year...

21 CFR 56.109(e)  45 CFR 46.109(e)
**What Should the IRB Consider During Continuing Review?**

- Are Both Risks and Anticipated Benefits Accurately Identified, Are They as Anticipated?
- Has New Information Become Available and Relevant to Risk/Benefit Determination?
- Have There Been Unanticipated Problems, Have They Been Reported?
- Has Study Recruitment Occurred as Anticipated, If Not Why?
- What is the Justification for Continuing the Research?

_Susan Kornetsky, Children's Hospital_

---

**Case Study**

- Study of Immune Modulators in Patients With Inflammatory Bowel Disease (IBD)
- Subject With IBD Get Blood Drawn
- Discussed on Continuation Review That Could Not Find Consents for 25 of 80 Subjects
- What Would You Do?

_Jeff Cooper, Huron_

---

**OHRP**

"Guidance on Continuing Review"

January 15, 2007

Types of Review:
The PI Changed Her Mind, What Should Happen?
Amendments and Revisions

What Should the IRB Consider When Reviewing Amendments?
- All Revisions/Amendments Require Review
- Require Approval Before Implemented Unless to Assure Immediate Safety of Subject(s)
- Understand Reason for Change
- Understand Whether the Change Impacts Risk/Benefit Assessment or Specific Findings
- Check to See if the Consent Requires Revision
- IRB Determines What Type of Review is Required

Susan Kornetsky, Children's Hospital

National Cancer Institute
Cancer Therapy Evaluation Program (CTEP)

- CTEP – Cooperative Groups (e.g. RTOG, SWOG, GOG)
- IRB Review of Protocol & Informed Consent Changes
  - March 20, 2008 Memorandum
  - September 29, 2008 Clarification
  - Issued By CTEP and OHRP
NCI CTEP: Action Letters

- PI Must Temporarily Suspend New Enrollment When CTEP Identifies New or Modified Risk That Requires Informed Consent Changes
- CTEP: Determines Expedited Vs. Full Review (IRB May Be More Stringent)
- CTEP: May ID Other Consent Form Changes That Require Suspension

Types of Review

- The PI Has a Single Subject Who Does Not Meet the Inclusion Criteria or the PI Wants to Change the Dosage Schedule to Accommodate a Single Subject’s Needs – What Should Happen?

Types of Review:
If There is an Adverse Event or Unanticipated Problem Involving Risk
OHRP

"Guidance on Reviewing and Reporting Unanticipated Problems Involving Risks to Subjects or Others and Adverse Events"

January 15, 2007


FDA: New Guidance

- "Guidance for Clinical Investigators, Sponsors, and IRBs Adverse Event Reporting – Improving Human Subject Protection"
  Draft – April 2007
  http://www.fda.gov/cber/gdlns/advreport.pdf

- Comments Due June 2007

Criteria For Approval

- Risks Minimized
- Risks Vs. Benefits
- Selection Equitable
- Informed Consent
- Consent Documentation
- Data Monitoring
- Privacy & Confidentiality
- Additional Safeguards / Vulnerable Subjects
Informed Consent: 6 Broad Categories

1. General Requirements
2. Basic Elements
3. Additional Elements
4. Alteration or Waiver of Process
5. Documentation
6. Waiver of Documentation

Informed Consent
General Requirements

- Subject or Legally Authorized Representative*
- Understandable Language
- Opportunity to Consider
- Minimize Coercion & Under Influence
- Avoid Exculpatory Language

*FDA Requires Date as Well as Signature

Basic Elements

- Research
  - Purpose/Duration
  - Procedures
  - Experimental
- Risks
- Benefits
- Alternatives

- Confidentiality
- Compensation for Injury (1Minimal Risk)
- Whom to Contact re:
  - Study, Subjects' Rights, Event of Injury
- Right to Refuse or Withdraw Without Penalty
**Additional Elements**

**Informed Consent**

- Currently Unforeseeable Risks
- Termination of Participation
- Additional Costs to Subjects
- Consequence of Withdrawal
- Informing of New Findings
- Approximate Number of Subjects

---

**What if PI Wants to:**

- Conduct Deception Study? (i.e., Withhold Information From the Subject)
- Review Medical Records Without Obtaining Informed Consent?

*Ada Sue Selkowitz, University of Kentucky*

---

**Common Rule/HHS Requirements***

**Waiving Informed Consent Process**

- No More Than Minimal Risk
- Rights and Welfare - Not Adversely Affected
- Research Could Not Be Practically Conducted Without Waiver
- Subjects Provided With Pertinent Information After Participation

*Not Adopted by FDA*
What if the PI Wants to:

- Interview Adolescent Prostitutes and Not Obtain Signed Forms?

Exceptions to Documentation (Form Only)*

- Consent is Only Record Linking Subject AND
- Breach of Confidentiality/Poses Risk AND
- Subject Should be Asked if Wants Documentation (Not FDA)

*Not Adopted By FDA

What if the PI Wants to:

- Collect Data Via Telephone Survey and Does Not Want to Obtain a Written Form?
Exceptions to Documentation (Form Only)*

- No More Than Minimal Risk AND
- Involves No Procedures for Which Consent Normally Required

FDA, OHIRP, & Common Rule

What Do You Do When...?
It is 5:00 PM on Friday. Physician Calls. She Has a Patient Who Was in a Car Wreck and Is Unconscious. Cannot Find a Legally Authorized Representative (LAR). Wants to Administer an Investigational Drug Without Informed Consent.

Ada Sue Selwitz, University of Kentucky

Exceptions Informed Consent
Single Patient — FDA Only*
21 CFR 50.23

- Both PI & MD Who is Not Participating Certify In Writing:
  - Life Threatening
  - Inability to Communicate or Obtain
  - Time Not Sufficient
  - No Alternate or Recognized Therapy

- Report to IRB 5 Working Days

*Not Adopted by 45 CFR 46/Common Rule
What Regulations Do You Apply if...

PI Proposes to Initiate a Study Which Enrolls Car Crash Victims and Requires That the Drug be Administered Immediately at the Scene of the Crash?

Adra Sue Solowitz, University of Kentucky

Acute Care
Informed Consent Waiver For Entire Study During Initial Review

• FDA 21 CFR 50.24
• DHHS 45 CFR Part 46.101(i)

11 Categories of Reports IRB Must Submit to:
• Institution
• Funding Agency/Sponsor
• Regulatory Agency
First 3 Categories are:
1. Unanticipated Problems Involving Risks to Subjects or Others
2. Serious or Continuing Noncompliance
3. Suspension or Termination of IRB Approval

11 Reporting Categories Continued:
4. Pregnant Women, Fetuses & Neonates Subpart B (If Applicable: Secretary HHS OHRP; Homeland Security)
6. Children Subpart D (If Applicable: Secretary HHS OHRP; Commissioner of FDA; US Department of Education; Homeland Security)

11 Reporting Categories Continued
7. Changes in IRB Membership (OHRP)
8. Certification of IRB Approval (Funding Agencies)
**Category 10: Specialized IRB Reporting**

- There are Numerous Additional Reporting Requirements that are Tied to Specialized Funding/Regulatory Agencies
- For Example, IRB Administrators at VA or VA Affiliated IRBs Have Additional Reporting Requirements
- IRB Administrator is Responsible for Identifying Additional Specialized Requirements

**Category 11:**

- Regulatory Agency Sends Institution a Request for a Report (Usually Due to Allegations of Noncompliance)

**IRB Records**

- Research Protocols
- Correspondence
- Continuing Review
- Meeting Minutes
- Membership
- Written procedures
- Significant New Findings
How Long Do You Maintain Records?

- Common Rule & FDA: Retain Three Years After Completion
- HIPAA: Six Years
- State Law: ?
- IRB Policy: ?

Objective

To Provide an Overview of Basic IRB Regulations
<table>
<thead>
<tr>
<th>Date</th>
<th>Title</th>
<th>Web link</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>October 16, 2008</td>
<td>OHRP Guidance on Engagement of Institutions In Human Subject Research</td>
<td><a href="http://www.hhs.gov/ohrp/humansubjects/guidance/engage08.html">http://www.hhs.gov/ohrp/humansubjects/guidance/engage08.html</a></td>
<td>Use to assess whether an assurance is needed in collaborative research</td>
</tr>
<tr>
<td>October 16, 2008</td>
<td>OHRP GUIDANCE ON RESEARCH INVOLVING CODED PRIVATE INFORMATION OR BIOLOGICAL SPECIMENS. This guidance has been updated to be consistent with OHRR'S OCTOBER 16, 2008 GUIDANCE ON ENGAGEMENT OF INSTITUTIONS IN HUMAN SUBJECTS RESEARCH ( Replaces OHRR'S AUGUST 10, 2004 guidance)</td>
<td><a href="http://www.hhs.gov/ohrp/humansubjects/guidance/cdebiol.pdf">http://www.hhs.gov/ohrp/humansubjects/guidance/cdebiol.pdf</a></td>
<td>Eliminates one example from 2004 and adds minor clarification</td>
</tr>
<tr>
<td>February 15, 2008</td>
<td>OHRP Statement regarding Quality Assurance Research</td>
<td><a href="http://www.hhs.gov/ohrp/news/recentnews.html#20080215">http://www.hhs.gov/ohrp/news/recentnews.html#20080215</a></td>
<td>Conclusion regarding Johns Hopkins hospital infection research</td>
</tr>
<tr>
<td>December 1, 2008</td>
<td>OHRP Draft Guidance for when Participation of Human Subjects is Discontinued</td>
<td><a href="http://www.hhs.gov/ohrp/requests/200811guidance.html">http://www.hhs.gov/ohrp/requests/200811guidance.html</a></td>
<td></td>
</tr>
<tr>
<td>Date</td>
<td>Description</td>
<td>URL</td>
<td>Notes</td>
</tr>
<tr>
<td>-----------------</td>
<td>-----------------------------------------------------------------------------------------------</td>
<td>----------------------------------------------------------------------</td>
<td>----------------------------------------------------------------------</td>
</tr>
<tr>
<td>Date</td>
<td>Title</td>
<td>Web Link</td>
<td>Comments</td>
</tr>
<tr>
<td>--------------------</td>
<td>-----------------------------------------------------------------------</td>
<td>-----------------------------------------------</td>
<td>-----------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td></td>
<td>Adverse Event Reporting - Improving Human Subject Protection</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Involving Risks to Subjects or Others and Adverse Events</td>
<td></td>
<td></td>
</tr>
<tr>
<td>September 27, 2007</td>
<td>Food &amp; Drug Administration Amendments Act (FDAAA) impacts</td>
<td><a href="http://www.fda.gov/cder/regulatory/FDAAA/default.htm">http://www.fda.gov/cder/regulatory/FDAAA/default.htm</a></td>
<td>Clinical Trial Databases/enhanced Postmarketing Safety - Risk Evaluation &amp; Mitigation Strategies (REMS)</td>
</tr>
<tr>
<td></td>
<td>investigators and sponsors; requires registration of clinical trials.</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Resources

<table>
<thead>
<tr>
<th>Title</th>
<th>Web Link</th>
</tr>
</thead>
<tbody>
<tr>
<td>CDER Guidance (new)</td>
<td><a href="http://www.fda.gov/cder/guidance/#newly_added">http://www.fda.gov/cder/guidance/#newly_added</a></td>
</tr>
<tr>
<td>CDER Guidance &amp; Recent</td>
<td><a href="http://www.fda.gov/cder/guidance/">http://www.fda.gov/cder/guidance/</a></td>
</tr>
<tr>
<td>Guidance</td>
<td></td>
</tr>
<tr>
<td>FDA Information Sheets</td>
<td><a href="http://www.fda.gov/oc/ohrt/irbs/default.htm">http://www.fda.gov/oc/ohrt/irbs/default.htm</a></td>
</tr>
<tr>
<td>OHRP NEWS</td>
<td><a href="http://www.hhs.gov/ohrp/news/">http://www.hhs.gov/ohrp/news/</a></td>
</tr>
<tr>
<td>OHRP Correspondence Website</td>
<td><a href="http://www.hhs.gov/ohrp/policy/correspond/">http://www.hhs.gov/ohrp/policy/correspond/</a></td>
</tr>
<tr>
<td>DHHS NIH HIPAA Guidance</td>
<td><a href="http://privacyruleandresearch.nih.gov/">http://privacyruleandresearch.nih.gov/</a></td>
</tr>
<tr>
<td>Website</td>
<td></td>
</tr>
<tr>
<td>DHHS HIPAA FAQ</td>
<td><a href="http://www.hhs.gov/hipaafaq/">http://www.hhs.gov/hipaafaq/</a></td>
</tr>
</tbody>
</table>
Office for Human Research Protections (OHRP)
Department of Health and Human Services (HHS)

Guidance on Reviewing and Reporting Unanticipated Problems
Involving Risks to Subjects or Others and Adverse Events

This guidance represents OHRP’s current thinking on this topic and should be viewed as recommendations unless specific regulatory requirements are cited. The use of the word must in OHRP guidance means that something is required under HHS regulations at 45 CFR part 46. The use of the word should in OHRP guidance means that something is recommended or suggested, but not required. An institution may use an alternative approach if the approach satisfies the requirements of the HHS regulations at 45 CFR part 46. OHRP is available to discuss alternative approaches at 240-453-6900 or 866-447-4777.

Date: January 15, 2007

Scope: This document applies to non-exempt human subjects research conducted or supported by HHS. It provides guidance on HHS regulations for the protection of human research subjects at 45 CFR part 46 related to the review and reporting of (a) unanticipated problems involving risks to subjects or others (hereinafter referred to as unanticipated problems); and (b) adverse events. In particular, this guidance clarifies that only a small subset of adverse events occurring in human subjects participating in research are unanticipated problems that must be reported under 45 CFR part 46. The guidance is intended to help ensure that the review and reporting of unanticipated problems and adverse events occur in a timely, meaningful way so that human subjects can be better protected from avoidable harms while reducing unnecessary burden.

The guidance addresses the following topics:

I. What are unanticipated problems?

II. What are adverse events?

III. How do you determine which adverse events are unanticipated problems?

IV. What are other important considerations regarding the reviewing and reporting of unanticipated problems and adverse events?

V. What is the appropriate time frame for reporting unanticipated problems to the institutional review board (IRB), appropriate institutional officials, the department or agency head (or designee), and OHRP?

VI. What should the IRB consider at the time of initial review with respect to adverse events?
VII. What should the IRB consider at the time of continuing review with respect to unanticipated problems and adverse events?

VIII. What should written IRB procedures include with respect to reporting unanticipated problems?

Appendices

Appendix A: Glossary of Key Terms

Appendix B: Examples of Unanticipated Problems that Do Not Involve Adverse Events and Need to be Reported Under the HHS Regulations at 45 CFR Part 46

Appendix C: Examples of Adverse Events that Do Not Represent Unanticipated Problems and Do Not Need to be Reported under the HHS Regulations at 45 CFR Part 46

Appendix D: Examples of Adverse Events that Represent Unanticipated Problems and Need to be Reported under the HHS Regulations at 45 CFR Part 46

NOTE: For some HHS-conducted or -supported research, the Food and Drug Administration (FDA) and the HHS agency conducting or supporting the research (e.g., the National Institutes of Health [NIH]) may have separate regulatory and policy requirements regarding the reporting of unanticipated problems and adverse events. Anyone needing guidance on the reporting requirements of FDA or other HHS agencies should contact these agencies directly. Furthermore, investigators and IRBs should be cognizant of any applicable state and local laws and regulations related to unanticipated problems and adverse events experienced by research subjects, as well as foreign requirements for research conducted outside the United States. OHRP recommends that investigators and IRBs consult with their legal advisors for guidance regarding pertinent state, local, and international laws and regulations.

Target Audience: IRBs, investigators, and HHS funding agencies that may be responsible for review, conduct, or oversight of human subjects research conducted or supported by HHS.

Regulatory Background:

HHS regulations for the protection of human subjects (45 CFR part 46) contain five specific requirements relevant to the review and reporting of unanticipated problems and adverse events:

(1) Institutions engaged in human subjects research conducted or supported by HHS must have written procedures for ensuring prompt reporting to the IRB, appropriate
institutional officials, and any supporting department or agency head of any unanticipated problem involving risks to subjects or others (45 CFR 46.103(b)(5)).

(2) For research covered by an assurance approved for federalwide use by OHRP, HHS regulations at 45 CFR 46.103(a) require that institutions promptly report any unanticipated problems to OHRP.

(3) In order to approve research conducted or supported by HHS, the IRB must determine, among other things, that:

(a) Risks to subjects are minimized (i) by using procedures which are consistent with sound research design and which do not unnecessarily expose subjects to risk, and (ii) whenever appropriate, by using procedures already being performed on the subject for diagnostic or treatment purposes (45 CFR 46.111(a)(1)).

(b) Risks to subjects are reasonable in relation to anticipated benefits, if any, to the subjects, and the importance of the knowledge that may reasonably be expected to result (45 CFR 46.111(a)(2)).

(c) When appropriate, the research plan makes adequate provision for monitoring the data collected to ensure the safety of subjects (45 CFR 46.111(a)(6)).

(4) An IRB must conduct continuing review of research conducted or supported by HHS at intervals appropriate to the degree of risk, but not less than once per year, and shall have authority to observe or have a third party observe the consent process and the research (45 CFR 46.109(e)).

(5) An IRB must have authority to suspend or terminate approval of research conducted or supported by HHS that is not being conducted in accordance with the IRB’s requirements or that has been associated with unexpected serious harm to subjects. Any suspension or termination of approval must include a statement of the reasons for the IRB’s action and must be reported promptly to the investigator, appropriate institutional officials, and any supporting department or agency head (45 CFR 46.113).
Guidance:

I. What are unanticipated problems?

The phrase “unanticipated problems involving risks to subjects or others” is found but not defined in the HHS regulations at 45 CFR part 46. OHRP considers unanticipated problems, in general, to include any incident, experience, or outcome that meets all of the following criteria:

1. unexpected (in terms of nature, severity, or frequency) given (a) the research procedures that are described in the protocol-related documents, such as the IRB-approved research protocol and informed consent document; and (b) the characteristics of the subject population being studied;

2. related or possibly related to participation in the research (in this guidance document, possibly related means there is a reasonable possibility that the incident, experience, or outcome may have been caused by the procedures involved in the research); and

3. suggests that the research places subjects or others at a greater risk of harm (including physical, psychological, economic, or social harm) than was previously known or recognized.

OHRP recognizes that it may be difficult to determine whether a particular incident, experience, or outcome is unexpected and whether it is related or possibly related to participation in the research. OHRP notes that an incident, experience, or outcome that meets the three criteria above generally will warrant consideration of substantive changes in the research protocol or informed consent process/document or other corrective actions in order to protect the safety, welfare, or rights of subjects or others. Examples of corrective actions or substantive changes that might need to be considered in response to an unanticipated problem include:

- changes to the research protocol initiated by the investigator prior to obtaining IRB approval to eliminate apparent immediate hazards to subjects;
- modification of inclusion or exclusion criteria to mitigate the newly identified risks;
- implementation of additional procedures for monitoring subjects;
- suspension of enrollment of new subjects;
- suspension of research procedures in currently enrolled subjects;
- modification of informed consent documents to include a description of newly recognized risks; and
- provision of additional information about newly recognized risks to previously enrolled subjects.
As discussed in the sections II and III below, only a small subset of adverse events occurring in human subjects participating in research will meet these three criteria for an unanticipated problem.

Furthermore, there are other types of incidents, experiences, and outcomes that occur during the conduct of human subjects research that represent unanticipated problems but are not considered adverse events. For example, some unanticipated problems involve social or economic harm instead of the physical or psychological harm associated with adverse events. In other cases, unanticipated problems place subjects or others at increased risk of harm, but no harm occurs. Appendix B provides examples of unanticipated problems that do not involve adverse events but must be reported under the HHS regulations at 45 CFR 46.103(a) and 46.103(b)(5).

II. What are adverse events?

The HHS regulations at 45 CFR part 46 do not define or use the term adverse event, nor is there a common definition of this term across government and non-government entities. In this guidance document, the term adverse event in general is used very broadly and includes any event meeting the following definition:

Any untoward or unfavorable medical occurrence in a human subject, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the subject’s participation in the research, whether or not considered related to the subject’s participation in the research (modified from the definition of adverse events in the 1996 International Conference on Harmonization E-6 Guidelines for Good Clinical Practice).

Adverse events encompass both physical and psychological harms. They occur most commonly in the context of biomedical research, although on occasion, they can occur in the context of social and behavioral research.

In the context of multicenter clinical trials, adverse events can be characterized as either internal adverse events or external adverse events. From the perspective of one particular institution engaged in a multicenter clinical trial, internal adverse events are those adverse events experienced by subjects enrolled by the investigator(s) at that institution, whereas external adverse events are those adverse events experienced by subjects enrolled by investigators at other institutions engaged in the clinical trial. In the context of a single-center clinical trial, all adverse events would be considered internal adverse events.

In the case of an internal adverse event at a particular institution, an investigator at that institution typically becomes aware of the event directly from the subject, another collaborating investigator at the same institution, or the subject’s healthcare provider. In the case of external adverse events, the investigators at all participating institutions learn of such events via reports
that are distributed by the sponsor or coordinating center of the multicenter clinical trials. At many institutions, reports of external adverse events represent the majority of adverse event reports currently being submitted by investigators to IRBs.

### III. How do you determine which adverse events are unanticipated problems?

In OHRP’s experience, most IRB members, investigators, and institutional officials understand the scope and meaning of the term adverse event in the research context, but lack a clear understanding of OHRP’s expectations for what, when, and to whom adverse events need to be reported as unanticipated problems, given the requirements of the HHS regulations at 45 CFR part 46.

The following Venn diagram summarizes the general relationship between adverse events and unanticipated problems:

![Venn Diagram]

**Under 45 CFR part 46: Do not report A; Report B and C.**

The diagram illustrates three key points:

- The vast majority of adverse events occurring in human subjects are not unanticipated problems (area A).
- A small proportion of adverse events are unanticipated problems (area B).
- Unanticipated problems include other incidents, experiences, and outcomes that are not adverse events (area C).

The key question regarding a particular adverse event is whether it meets the three criteria described in section I and therefore represents an unanticipated problem. To determine whether an adverse event is an unanticipated problem, the following questions should be asked:
Is the adverse event unexpected?
Is the adverse event related or possibly related to participation in the research?
Does the adverse event suggest that the research places subjects or others at a greater risk of harm than was previously known or recognized?

If the answer to all three questions is yes, then the adverse event is an unanticipated problem and must be reported to appropriate entities under the HHS regulations at 45 CFR 46.103(a) and 46.103(b)(5). The next three sub-sections discuss the assessment of these three questions.

A. Assessing whether an adverse event is unexpected

In this guidance document, OHRP defines unexpected adverse event as follows:

Any adverse event occurring in one or more subjects participating in a research protocol, the nature, severity, or frequency of which is not consistent with either:

(1) the known or foreseeable risk of adverse events associated with the procedures involved in the research that are described in (a) the protocol-related documents, such as the IRB-approved research protocol, any applicable investigator brochure, and the current IRB-approved informed consent document, and (b) other relevant sources of information, such as product labeling and package inserts; or

(2) the expected natural progression of any underlying disease, disorder, or condition of the subject(s) experiencing the adverse event and the subject’s predisposing risk factor profile for the adverse event.

(Modified from the definition of unexpected adverse drug experience in FDA regulations at 21 CFR 312.32(a).)

Examples of unexpected adverse events under this definition include the following:

- liver failure due to diffuse hepatic necrosis occurring in a subject without any underlying liver disease would be an unexpected adverse event (by virtue of its unexpected nature) if the protocol-related documents and other relevant sources of information did not identify liver disease as a potential adverse event;
- Hodgkin’s disease (HD) occurring in a subject without predisposing risk factors for HD would be an unexpected adverse event (by virtue of its unexpected nature) if the protocol-related documents and other relevant sources of information only referred to acute myelogenous leukemia as a potential adverse event; and
- liver failure due to diffuse hepatic necrosis occurring in a subject without any underlying liver disease would be an unexpected adverse event (by virtue of its unexpected greater
severity) if the protocol-related documents and other relevant sources of information only referred to elevated hepatic enzymes or hepatitis as potential adverse events related to the procedures involved in the research.

In comparison, prolonged severe neutropenia and opportunistic infections occurring in subjects administered an experimental chemotherapy regimen as part of an oncology clinical trial would be examples of expected adverse events if the protocol-related documents described prolonged severe neutropenia and opportunistic infections as common risks for all subjects.

OHRP recognizes that it may be difficult to determine whether a particular adverse event is unexpected. OHRP notes that for many studies, determining whether a particular adverse event is unexpected by virtue of an unexpectedly higher frequency can only be done through an analysis of appropriate data on all subjects enrolled in the study.

In OHRP’s experience the vast majority of adverse events occurring in the context of research are expected in light of (1) the known toxicities and side effects of the research procedures; (2) the expected natural progression of subjects’ underlying diseases, disorders, and conditions; and (3) subjects’ predisposing risk factor profiles for the adverse events. Thus, most individual adverse events do not meet the first criterion for an unanticipated problem and do not need to be reported under the HHS regulations 45 CFR part 46.103(a) and 46.103(b)(5) (see examples (1)-(4) in Appendix C).

B. Assessing whether an adverse event is related or possibly related to participation in research

Adverse events may be caused by one or more of the following:

(1) the procedures involved in the research;
(2) an underlying disease, disorder, or condition of the subject; or
(3) other circumstances unrelated to either the research or any underlying disease, disorder, or condition of the subject.

In general, adverse events that are determined to be at least partially caused by (1) would be considered related to participation in the research, whereas adverse events determined to be solely caused by (2) or (3) would be considered unrelated to participation in the research.

For example, for subjects with cancer participating in oncology clinical trials testing chemotherapy drugs, neutropenia and anemia are common adverse events related to participation in the research. Likewise, if a subject with cancer and diabetes mellitus participates in an oncology clinical trial testing an investigational chemotherapy agent and experiences a severe hypoglycemia reaction that is determined to be caused by an interaction between the subject’s
diabetes medication and the investigational chemotherapy agent, such a hypoglycemic reaction would be another example of an adverse event related to participation in the research.

In contrast, for subjects with cancer enrolled in a non-interventional, observational research registry study designed to collect longitudinal morbidity and mortality outcome data on the subjects, the death of a subject from progression of the cancer would be an adverse event that is related to the subject’s underlying disease and is unrelated to participation in the research. Finally, the death of a subject participating in the same cancer research registry study from being struck by a car while crossing the street would be an adverse event that is unrelated to both participation in the research and the subject’s underlying disease.

Determinations about the relatedness of adverse events to participation in research commonly result in probability statements that fall along a continuum between definitely related to the research and definitely unrelated to participation in the research. OHRP considers possibly related to participation in the research to be an important threshold for determining whether a particular adverse event represents an unanticipated problem. In this guidance document, OHRP defines possibly related as follows:

There is a reasonable possibility that the adverse event may have been caused by the procedures involved in the research (modified from the definition of associated with use of the drug in FDA regulations at 21 CFR 312.32(a)).

OHRP recognizes that it may be difficult to determine whether a particular adverse event is related or possibly related to participation in the research.

Many individual adverse events occurring in the context of research are not related to participation in the research and, therefore, do not meet the second criterion for an unanticipated problem and do not need to be reported under the HHS regulations 45 CFR part 46.103(a) and 46.103(b)(5) (see examples (5) and (6) in Appendix C).

C. Assessing whether an adverse event suggests that the research places subjects or others at a greater risk of harm than was previously known or recognized

The first step in assessing whether an adverse event meets the third criterion for an unanticipated problem is to determine whether the adverse event is serious.

In this guidance document, OHRP defines serious adverse event as any adverse event that:

(1) results in death;
(2) is life-threatening (places the subject at immediate risk of death from the event as it occurred);
(3) results in inpatient hospitalization or prolongation of existing hospitalization;
OHRP Guidance on Unanticipated Problems and Adverse Events
January 15, 2007
Page 10 of 28

(4) results in a persistent or significant disability/incapacity;
(5) results in a congenital anomaly/birth defect; or
(6) based upon appropriate medical judgment, may jeopardize the subject’s health and
may require medical or surgical intervention to prevent one of the other outcomes listed
in this definition (examples of such events include allergic bronchospasm requiring
intensive treatment in the emergency room or at home, blood dyscrasias or convulsions
that do not result in inpatient hospitalization, or the development of drug dependency or
drug abuse).

(Modified from the definition of serious adverse drug experience in FDA regulations at 21 CFR
312.32(a).)

OHRP considers adverse events that are unexpected, related or possibly related to participation
in research, and serious to be the most important subset of adverse events representing
unanticipated problems because such events always suggest that the research places subjects or
others at a greater risk of physical or psychological harm than was previously known or
recognized and routinely warrant consideration of substantive changes in the research protocol or
informed consent process/document or other corrective actions in order to protect the safety,
welfare, or rights of subjects (see examples (1)-(4) in section Appendix D).

Furthermore, OHRP notes that IRBs have authority to suspend or terminate approval of research
that, among other things, has been associated with unexpected serious harm to subjects (45 CFR
46.113). In order for IRBs to exercise this important authority in a timely manner, they must be
informed promptly of those adverse events that are unexpected, related or possibly related to
participation in the research, and serious (45 CFR 46.103(b)(5)).

However, other adverse events that are unexpected and related or possibly related to participation
in the research, but not serious, would also be unanticipated problems if they suggest that the
research places subjects or others at a greater risk of physical or psychological harm than was
previously known or recognized. Again, such events routinely warrant consideration of
substantive changes in the research protocol or informed consent process/document or other
corrective actions in order to protect the safety, welfare, or rights of subjects or others (see
examples (5) and (6) in Appendix D).

The flow chart below provides an algorithm for determining whether an adverse event represents
an unanticipated problem that needs to be reported under HHS regulations at 45 CFR part 46.
Algorithm for Determining Whether an Adverse Event is an Unanticipated Problem

An adverse event occurs in one or more subjects.

1. Is the adverse event unexpected in nature, severity, or frequency?
   - NO
   - YES

2. Is the adverse event related or possibly related to participation in the research?
   - NO
   - YES

3. Does the adverse event suggest that the research places subjects or others at a greater risk of physical or psychological harm than was previously known or recognized? NOTE: If the adverse event is serious, the answer is always “YES.”
   - YES
   - NO

⚠️ Report the adverse event as an unanticipated problem under 45 CFR part 46

STOP
The adverse event is not an unanticipated problem and need not be reported under 45 CFR part 46
IV. What are other important considerations regarding the reviewing and reporting of unanticipated problems and adverse events?

A. Reporting of internal adverse events by investigators to IRBs

For an internal adverse event, a local investigator typically becomes aware of the event directly from the subject, another collaborating local investigator, or the subject’s healthcare provider.

Upon becoming aware of an internal adverse event, the investigator should assess whether the adverse event represents an unanticipated problem following the guidelines described in section III above. If the investigator determines that the adverse event represents an unanticipated problem, the investigator must report it promptly to the IRB (45 CFR 46.103(b)(5)).

Regardless of whether the internal adverse event is determined to be an unanticipated problem, the investigator also must ensure that the adverse event is reported to a monitoring entity (e.g., the research sponsor, a coordinating or statistical center, an independent medical monitor, or a DSMB/DMC) if required under the monitoring provisions described in the IRB-approved protocol or by institutional policy.

If the investigator determines that an adverse event is not an unanticipated problem, but the monitoring entity subsequently determines that the adverse event does in fact represent an unanticipated problem (for example, due to an unexpectedly higher frequency of the event), the monitoring entity should report this determination to the investigator, and such reports must be promptly submitted by the investigator to the IRB (45 CFR 46.103(b)(5)).

B. Reporting of external adverse events by investigators to IRBs

Investigators and IRBs at many institutions routinely receive a large volume of reports of external adverse events experienced by subjects enrolled in multicenter clinical trials. These external adverse event reports frequently represent the majority of adverse event reports submitted by investigators to IRBs. OHRP notes that reports of individual external adverse events often lack sufficient information to allow investigators or IRBs at each institution engaged in a multicenter clinical trial to make meaningful judgments about whether the adverse events are unexpected, are related or possibly related to participation in the research, or suggest that the research places subjects or others at a greater risk of physical or psychological harm than was previously known or recognized.

OHRP advises that it is neither useful nor necessary under the HHS regulations at 45 CFR part 46 for reports of individual adverse events occurring in subjects enrolled in multicenter studies to be distributed routinely to investigators or IRBs at all institutions conducting the research. Individual adverse events should only be reported to investigators and IRBs at all institutions when a determination has been made that the events meet the criteria for an unanticipated
problem. In general, the investigators and IRBs at all these institutions are not appropriately situated to assess the significance of individual external adverse events. Ideally, adverse events occurring in subjects enrolled in a multicenter study should be submitted for review and analysis to a monitoring entity (e.g., the research sponsor, a coordinating or statistical center, or a DSMB/DMC) in accordance with a monitoring plan described in the IRB-approved protocol.

Only when a particular adverse event or series of adverse events is determined to meet the criteria for an unanticipated problem should a report of the adverse event(s) be submitted to the IRB at each institution under the HHS regulations at 45 CFR part 46. Typically, such reports to the IRBs are submitted by investigators. OHRP recommends that any distributed reports include: (1) a clear explanation of why the adverse event or series of adverse events has been determined to be an unanticipated problem; and (2) a description of any proposed protocol changes or other corrective actions to be taken by the investigators in response to the unanticipated problem.

When an investigator receives a report of an external adverse event, the investigator should review the report and assess whether it identifies the adverse event as being:

(1) unexpected;

(2) related or possibly related to participation in the research; and

(3) serious or otherwise one that suggests that the research places subjects or others at a greater risk of physical or psychological harm than was previously known or recognized.

Only external adverse events that are identified in the report as meeting all three criteria must be reported promptly by the investigator to the IRB as unanticipated problems under HHS regulations at 45 CFR 46.103(b)(5). OHRP expects that individual external adverse events rarely will meet these criteria for an unanticipated problem.

C. Reporting of other unanticipated problems (not related to adverse events) by investigators to IRBs

Upon becoming aware of any other incident, experience, or outcome (not related to an adverse event; see Appendix B for examples) that may represent an unanticipated problem, the investigator should assess whether the incident, experience, or outcome represents an unanticipated problem by applying the criteria described in section I. If the investigator determines that the incident, experience, or outcome represents an unanticipated problem, the investigator must report it promptly to the IRB (45 CFR 46.103(b)(5)).
D. Content of reports of unanticipated problems submitted to IRBs

OHRP recommends that investigators include the following information when reporting an adverse event, or any other incident, experience, or outcome as an unanticipated problem to the IRB:

(1) appropriate identifying information for the research protocol, such as the title, investigator’s name, and the IRB project number;

(2) a detailed description of the adverse event, incident, experience, or outcome;

(3) an explanation of the basis for determining that the adverse event, incident, experience, or outcome represents an unanticipated problem; and

(4) a description of any changes to the protocol or other corrective actions that have been taken or are proposed in response to the unanticipated problem.

E. Changes to a multicenter research protocol that are proposed by an investigator at one institution in response to an unanticipated problem

For multicenter research protocols, if a local investigator at one institution engaged in the research independently proposes changes to the protocol or informed consent document in response to an unanticipated problem, the investigator should consult with the study sponsor or coordinating center regarding the proposed changes because changes at one site could have significant implications for the entire research study.

F. IRB review and further reporting of unanticipated problems

Once reported to the IRB, further review and reporting of any unanticipated problems must proceed in accordance with the institution’s written procedures for reporting unanticipated problems, as required by HHS regulations at 45 CFR 46.105(b). The HHS regulations at 45 CFR part 46 do not specify requirements for how such unanticipated problems are reviewed by the IRB. Therefore, IRBs are free to implement a wide range of procedures for reviewing unanticipated problems, including review by the IRB chairperson or another IRB member, a subcommittee of the IRB, or the convened IRB, among others. When reviewing a report of an unanticipated problem, the IRB should consider whether the affected research protocol still satisfies the requirements for IRB approval under HHS regulations at 45 CFR 46.111. In particular, the IRB should consider whether risks to subjects are still minimized and reasonable in relation to the anticipated benefits, if any, to the subjects and the importance of the knowledge that may reasonably be expected to result.
When reviewing a particular incident, experience, or outcome reported as an unanticipated problem by the investigator, the IRB may determine that the incident, experience, or outcome does not meet all three criteria for an unanticipated problem. In such cases, further reporting to appropriate institutional officials, the department or agency head (or designee), and OHRP would not be required under HHS regulations at 45 CFR 46.103(a) and 46.103(b)(5).

The IRB has authority, under HHS regulations at 45 CFR 46.109(a), to require, as a condition of continued approval by the IRB, submission of more detailed information by the investigator(s), the sponsor, the study coordinating center, or DSMB/DMC about any adverse event or unanticipated problem occurring in a research protocol.

Any proposed changes to a research study in response to an unanticipated problem must be reviewed and approved by the IRB before being implemented, except when necessary to eliminate apparent immediate hazards to subjects. If the changes are more than minor, the changes must be reviewed and approved by the convened IRB (45 CFR 46.103(b)(4) and 46.110(a)). OHRP recommends that for multicenter research protocols, if the IRB proposes changes to the protocol or informed consent documents/process in addition to those proposed by the study sponsor, coordinating center, or local investigator, the IRB should request in writing that the local investigator discuss the proposed modifications with the study sponsor or coordinating center and submit a response or necessary modifications for review by the IRB.

Institutions must have written procedures for reporting unanticipated problems to appropriate institutional officials (45 CFR 46.103(b)(5)). The regulations do not specify who the appropriate institutional officials are. Institutions may develop written procedures that specify different institutional officials as being appropriate for different types of unanticipated problems. For example, an institution could develop written procedures designating the IRB chairperson and members as the only appropriate institutional officials to whom external adverse events that are unanticipated problems are to be reported, and designating the Vice President for Research as an additional appropriate institutional official to whom internal adverse events that are unanticipated problems are to be reported by the IRB chairperson.

G. Reporting unanticipated problems to OHRP and supporting agency heads (or designees)

Unanticipated problems occurring in research covered by an OHRP-approved assurance also must be reported by the institution to the supporting HHS agency head (or designee) and OHRP (45 CFR 46.103(a)). Typically, the IRB chairperson or administrator, or another appropriate institutional official identified under the institution’s written IRB procedures, is responsible for reporting unanticipated problems to the supporting HHS agency head (or designee) and OHRP. For further information on reporting to OHRP, see the Guidance on Reporting Incidents to OHRP at http://www.hhs.gov/ohrp/policy/incidreport_ohrp.html.
For multicenter research projects, only the institution at which the subject(s) experienced an adverse event determined to be an unanticipated problem (or the institution at which any other type of unanticipated problem occurred) must report the event to the supporting agency head (or designee) and OHRP (45 CFR 46.103(b)(5)). Alternatively, the central monitoring entity may be designated to submit reports of unanticipated problems to the supporting agency head (or designee) and OHRP.

V. What is the appropriate time frame for reporting unanticipated problems to the IRB, appropriate institutional officials, the department or agency head (or designee), and OHRP?

The HHS regulations at 46.103(b)(5) require written procedures for ensuring prompt reporting of unanticipated problems to the IRB, appropriate institutional officials, any supporting department or agency head (or designee), and OHRP. The purpose of prompt reporting is to ensure that appropriate steps are taken in a timely manner to protect other subjects from avoidable harm.

The regulations do not define prompt. The appropriate time frame for satisfying the requirement for prompt reporting will vary depending on the specific nature of the unanticipated problem, the nature of the research associated with the problem, and the entity to which reports are to be submitted. For example, an unanticipated problem that resulted in a subject’s death or was potentially life-threatening generally should be reported to the IRB within a shorter time frame than other unanticipated problems that were not life-threatening. Therefore, OHRP recommends the following guidelines in order to satisfy the requirement for prompt reporting:

1. Unanticipated problems that are serious adverse events should be reported to the IRB within 1 week of the investigator becoming aware of the event.

2. Any other unanticipated problem should be reported to the IRB within 2 weeks of the investigator becoming aware of the problem.

3. All unanticipated problems should be reported to appropriate institutional officials (as required by an institution’s written reporting procedures), the supporting agency head (or designee), and OHRP within one month of the IRB’s receipt of the report of the problem from the investigator.

OHRP notes that, in some cases, the requirements for prompt reporting may be met by submitting a preliminary report to the IRB, appropriate institutional officials, the supporting HHS agency head (or designee), and OHRP, with a follow-up report submitted at a later date when more information is available. Determining the appropriate time frame for reporting a particular unanticipated problem requires careful judgment by persons knowledgeable about human subject protections. The primary consideration in making these judgments is the need to take timely action to prevent avoidable harms to other subjects.
VI. What should the IRB consider at the time of initial review with respect to adverse events?

Before research is approved and the first subject enrolled, the investigator(s) and the IRB should give appropriate consideration to the spectrum of adverse events that might occur in subjects. In particular, in order to make the determinations required for approval of research under HHS regulations at 45 CFR 46.111(a)(1), (2), and (6), the IRB needs to receive and review sufficient information regarding the risk profile of the proposed research study, including the type, probability, and expected level of severity of the adverse events that may be caused by the procedures involved in the research. The investigator also should describe how the risks of the research will be minimized.

In addition, depending upon the risks of the research and the likelihood that the research could involve risks to subjects that are unforesable, the IRB must ensure, if appropriate, that the research includes adequate provisions for monitoring the data collected to ensure the safety of subjects (45 CFR 46.111(a)(6)). Such provisions typically would include monitoring, among other things, adverse events and unanticipated problems that may occur in subjects enrolled in the research. The HHS regulations at 45 CFR part 46 do not require that the IRB conduct such monitoring, and OHRP believes that, in general, the IRB is not the appropriate entity to monitor research.

OHRP notes that adequate monitoring provisions for research, if deemed appropriate by the IRB, might include one or more of the following elements, among others:

(1) The type of data or events that are to be captured under the monitoring provisions.

(2) The entity responsible for monitoring the data collected, including data related to unanticipated problems and adverse events, and their respective roles (e.g., the investigators, the research sponsor, a coordinating or statistical center, an independent medical monitor, a DSMB/DMC, and/or some other entity). (OHRP notes that the IRB has authority to observe or have a third party observe the research (45 CFR 46.109(e)).

(3) The time frames for reporting adverse events and unanticipated problems to the monitoring entity.

(4) The frequency of assessments of data or events captured by the monitoring provisions.

(5) Definition of specific triggers or stopping rules that will dictate when some action is required.
(6) As appropriate, procedures for communicating to the IRB(s), the study sponsor, the investigator(s), and other appropriate officials the outcome of the reviews by the monitoring entity.

The monitoring provisions should be tailored to the expected risks of the research; the type of subject population being studied; and the nature, size (in terms of projected subject enrollment and the number of institutions enrolling subjects), and complexity of the research protocol. For example, for a multicenter clinical trial involving a high level of risk to subjects, frequent monitoring by a DSMB/DMC may be appropriate, whereas for research involving no more than minimal risk to subjects, it may be appropriate to not include any monitoring provisions.

VII. What should the IRB consider at the time of continuing review with respect to unanticipated problems and adverse events?

For non-exempt research conducted or supported by HHS, the IRB must conduct continuing review of research at intervals appropriate to the degree of risk, but not less than once per year (45 CFR 46.109(e)). At the time of continuing review, the IRB should ensure that the criteria for IRB approval under HHS regulations at 45 CFR 46.111 continue to be satisfied. In particular, the IRB needs to determine whether any new information has emerged — either from the research itself or from other sources — that could alter the IRB’s previous determinations, particularly with respect to risk to subjects. Information regarding any unanticipated problems that have occurred since the previous IRB review in most cases will be pertinent to the IRB’s determinations at the time of continuing review.

It may also be appropriate for the IRB at the time of continuing review to confirm that any provisions under the previously approved protocol for monitoring study data to ensure safety of subjects have been implemented and are working as intended (e.g., the IRB could require that the investigator provide a report from the monitoring entity described in the IRB-approved protocol).

OHRP recommends that, among other things, a summary of any unanticipated problems and available information regarding adverse events and any recent literature that may be relevant to the research be included in continuing review reports submitted to the IRB by investigators. OHRP notes that the amount of detail provided in such a summary will vary depending on the type of research being conducted. In many cases, such a summary could be a simple brief statement that there have been no unanticipated problems and that adverse events have occurred at the expected frequency and level of severity as documented in the research protocol, the informed consent document, and any investigator brochure.

OHRP recognizes that local investigators participating in multicenter clinical trials usually are unable to prepare a meaningful summary of adverse events for their IRBs because study-wide information regarding adverse events is not readily available to them. In such circumstances,
when the clinical trial is subject to oversight by a monitoring entity (e.g., the research sponsor, a coordinating or statistical center, or a DSMB/DMC), OHRP recommends that at the time of continuing review local investigators submit to their IRBs a current report from the monitoring entity. OHRP further recommends that such reports include the following:

(1) a statement indicating what information (e.g., study-wide adverse events, interim findings, and any recent literature that may be relevant to the research) was reviewed by the monitoring entity;

(2) the date of the review; and

(3) the monitoring entity’s assessment of the information reviewed.

For additional details about OHRP’s guidance on continuing review, see http://www.hhs.gov/ohrp/humansubjects/guidance/contrev0107.htm.

VIII. What should written IRB procedures include with respect to reporting unanticipated problems?

Written IRB procedures should provide a step-by-step description with key operational details for complying with the reporting requirements described in HHS regulations at 45 CFR 46.103(b)(5). Important operational details for the required reporting procedures should include:

(1) The type of information that is to be included in reports of unanticipated problems.

(2) A description of which office(s) or individual(s) is responsible for promptly reporting unanticipated problems to the IRB, appropriate institutional officials, any supporting department or agency heads (or designees), and OHRP.

(3) A description of the required time frame for accomplishing the reporting requirements for unanticipated problems.

(4) The range of the IRB’s possible actions in response to reports of unanticipated problems.

OHRP notes that many institutions have written IRB procedures for reporting adverse events, but do not address specifically the reporting requirements for unanticipated problems. Such institutions should expand their written IRB procedures to include reporting requirements for unanticipated problems.
Appendix A
Glossary for Key Terms

Adverse event: Any untoward or unfavorable medical occurrence in a human subject, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the subject’s participation in the research, whether or not considered related to the subject’s participation in the research (modified from the definition of adverse events in the 1996 International Conference on Harmonization E-6 Guidelines for Good Clinical Practice).

External adverse event: From the perspective of one particular institution engaged in a multicenter clinical trial, external adverse events are those adverse events experienced by subjects enrolled by investigators at other institutions engaged in the clinical trial.

Internal adverse event: From the perspective of one particular institution engaged in a multicenter clinical trial, internal adverse events are those adverse events experienced by subjects enrolled by the investigator(s) at that institution. In the context of a single-center clinical trial, all adverse events would be considered internal adverse events.

Possibly related to the research: There is a reasonable possibility that the adverse event, incident, experience or outcome may have been caused by the procedures involved in the research (modified from the definition of associated with use of the drug in FDA regulations at 21 CFR 312.32(a)).

Serious adverse event: Any adverse event temporally associated with the subject’s participation in research that meets any of the following criteria:

(1) results in death;
(2) is life-threatening (places the subject at immediate risk of death from the event as it occurred);
(3) requires inpatient hospitalization or prolongation of existing hospitalization;
(4) results in a persistent or significant disability/incapacity;
(5) results in a congenital anomaly/birth defect; or
(6) any other adverse event that, based upon appropriate medical judgment, may jeopardize the subject’s health and may require medical or surgical intervention to prevent one of the other outcomes listed in this definition (examples of such events include allergic bronchospasm requiring intensive treatment in the emergency room or at home, blood dyscrasias or convulsions that do not result in inpatient hospitalization, or the development of drug dependency or drug abuse).

(Modified from the definition of serious adverse drug experience in FDA regulations at 21 CFR 312.32(a).)
**Unanticipated problem involving risks to subjects or others:** Any incident, experience, or outcome that meets all of the following criteria:

1. unexpected (in terms of nature, severity, or frequency) given (a) the research procedures that are described in the protocol-related documents, such as the IRB-approved research protocol and informed consent document; and (b) the characteristics of the subject population being studied;
2. related or possibly related to a subject’s participation in the research; and
3. suggests that the research places subjects or others at a greater risk of harm (including physical, psychological, economic, or social harm) related to the research than was previously known or recognized.

**Unexpected adverse event:** Any adverse event occurring in one or more subjects in a research protocol, the nature, severity, or frequency of which is not consistent with either:

1. the known or foreseeable risk of adverse events associated with the procedures involved in the research that are described in (a) the protocol–related documents, such as the IRB-approved research protocol, any applicable investigator brochure, and the current IRB-approved informed consent document, and (b) other relevant sources of information, such as product labeling and package inserts; or
2. the expected natural progression of any underlying disease, disorder, or condition of the subject(s) experiencing the adverse event and the subject’s predisposing risk factor profile for the adverse event.

(Modified from the definition of *unexpected adverse drug experience* in FDA regulations at 21 CFR 312.32(a).)
Appendix B
Examples of Unanticipated Problems that Do Not Involve Adverse Events and Need to be Reported Under the HHS Regulations at 45 CFR Part 46

(1) An investigator conducting behavioral research collects individually identifiable sensitive information about illicit drug use and other illegal behaviors by surveying college students. The data are stored on a laptop computer without encryption, and the laptop computer is stolen from the investigator’s car on the way home from work. This is an unanticipated problem that must be reported because the incident was (a) unexpected (i.e., the investigators did not anticipate the theft); (b) related to participation in the research; and (c) placed the subjects at a greater risk of psychological and social harm from the breach in confidentiality of the study data than was previously known or recognized.

(2) As a result of a processing error by a pharmacy technician, a subject enrolled in a multicenter clinical trial receives a dose of an experimental agent that is 10-times higher than the dose dictated by the IRB-approved protocol. While the dosing error increased the risk of toxic manifestations of the experimental agent, the subject experienced no detectable harm or adverse effect after an appropriate period of careful observation. Nevertheless, this constitutes an unanticipated problem for the institution where the dosing error occurred that must be reported to the IRB, appropriate institutional officials, and OHRP because the incident was (a) unexpected; (b) related to participation in the research; and (c) placed subject at a greater risk of physical harm than was previously known or recognized.

(3) Subjects with cancer are enrolled in a phase 2 clinical trial evaluating an investigational biologic product derived from human sera. After several subjects are enrolled and receive the investigational product, a study audit reveals that the investigational product administered to subjects was obtained from donors who were not appropriately screened and tested for several potential viral contaminants, including the human immunodeficiency virus and the hepatitis B virus. This constitutes an unanticipated problem that must be reported because the incident was (a) unexpected; (b) related to participation in the research; and (c) placed subjects and others at a greater risk of physical harm than was previously known or recognized.

The events described in the above examples were unexpected in nature, related to participation in the research, and resulted in new circumstances that increased the risk of harm to subjects. In all of these examples, the unanticipated problems warranted consideration of substantive changes in the research protocol or informed consent process/document or other corrective actions in order to protect the safety, welfare, or rights of subjects. In addition, the third example may have presented unanticipated risks to others (e.g., the sexual partners of the subjects) in addition to the subjects. In each of these examples, while these events may not have caused any detectable harm or adverse effect to subjects or others, they nevertheless represent unanticipated problems and should be promptly reported to the IRB, appropriate institutional officials, the supporting
agency head and OHRP in accordance with HHS regulations at 45 CFR 46.103(a) and 46.103(b)(5).
Appendix C

Examples of Adverse Events that Do Not Represent Unanticipated Problems and Do Not Need to be Reported under the HHS Regulations at 45 CFR Part 46

(1) A subject participating in a phase 3, randomized, double-blind, controlled clinical trial comparing the relative safety and efficacy of a new chemotherapy agent combined with the current standard chemotherapy regimen, versus placebo combined with the current standard chemotherapy regimen, for the management of multiple myeloma develops neutropenia and sepsis. The subject subsequently develops multi-organ failure and dies. Prolonged bone marrow suppression resulting in neutropenia and risk of life-threatening infections is a known complication of the chemotherapy regimens being tested in this clinical trial and these risks are described in the IRB-approved protocol and informed consent document. The investigators conclude that the subject’s infection and death are directly related to the research interventions. A review of data on all subjects enrolled so far reveals that the incidence of severe neutropenia, infection, and death are within the expected frequency. This example is not an unanticipated problem because the occurrence of severe infections and death — in terms of nature, severity, and frequency — was expected.

(2) A subject enrolled in a phase 3, randomized, double-blind, placebo-controlled clinical trial evaluating the safety and efficacy of a new investigational anti-inflammatory agent for management of osteoarthritis develops severe abdominal pain and nausea one month after randomization. Subsequent medical evaluation reveals gastric ulcers. The IRB-approved protocol and informed consent document for the study indicated that the there was a 10% chance of developing mild to moderate gastritis and a 2% chance of developing gastric ulcers for subjects assigned to the active investigational agent. The investigator concludes that the subject’s gastric ulcers resulted from the research intervention and withdraws the subject from the study. A review of data on all subjects enrolled so far reveals that the incidence of gastritis and gastric ulcer are within the expected frequency. This example is not an unanticipated problem because the occurrence of gastric ulcers — in terms of nature, severity, and frequency — was expected.

(3) A subject is enrolled in a phase 3, randomized clinical trial evaluating the relative safety and efficacy of vascular stent placement versus carotid endarterectomy for the treatment of patients with severe carotid artery stenosis and recent transient ischemic attacks. The patient is assigned to the stent placement study group and undergoes stent placement in the right carotid artery. Immediately following the procedure, the patient suffers a severe ischemic stroke resulting in complete left-sided paralysis. The IRB-approved protocol and informed consent document for the study indicated that there was a 5-10% chance of stroke for both study groups. To date, 25 subjects have been enrolled in the clinical trial, and 2 have suffered a stroke shortly after undergoing the study intervention, including the current subject. The DSMB responsible for monitoring the study concludes that the subject’s stroke resulted from the research intervention. This example is not an unanticipated problem.
because the occurrence of stroke was expected and the frequency at which strokes were occurring in subjects enrolled so far was at the expected level.

(4) An investigator is conducting a psychology study evaluating the factors that affect reaction times in response to auditory stimuli. In order to perform the reaction time measurements, subjects are placed in a small, windowless soundproof booth and asked to wear headphones. The IRB-approved protocol and informed consent document describe claustrophobic reactions as one of the risks of the research. The twentieth subject enrolled in the research experiences significant claustrophobia, resulting in the subject withdrawing from the research. This example is not an unanticipated problem because the occurrence of the claustrophobic reactions— in terms of nature, severity, and frequency— was expected.

(5) A subject with advanced renal cell carcinoma is enrolled in a study evaluating the effects of hypnosis for the management of chronic pain in cancer patients. During the subject’s initial hypnosis session in the pain clinic, the subject suddenly develops acute chest pain and shortness of breath, followed by loss of consciousness. The subject suffers a cardiac arrest and dies. An autopsy reveals that the patient died from a massive pulmonary embolus, presumed related to the underlying renal cell carcinoma. The investigator concludes that the subject’s death is unrelated to participation in the research. This example is not an unanticipated problem because the subject’s pulmonary embolus and death were attributed to causes other than the research interventions.

(6) An investigator performs prospective medical chart reviews to collect medical data on premature infants in a neonatal intensive care unit (NICU) for a research registry. An infant, about whom the investigator is collecting medical data for the registry, dies as the result of an infection that commonly occurs in the NICU setting. This example is not an unanticipated problem because the death of the subject is not related to participation in the research, but is most likely related to the infant’s underlying medical condition.

NOTE: For purposes of illustration, the case examples provided above represent generally unambiguous examples of adverse events that are not unanticipated problems. OHRP recognizes that it may be difficult to determine whether a particular adverse event is unexpected and whether it is related or possibly related to participation in the research. In addition, the assessment of the relationship between the expected and actual frequency of a particular adverse event must take into account a number of factors including the uncertainty of the expected frequency estimates, the number and type of individuals enrolled in the study, and the number of subjects who have experienced the adverse event.
Appendix D
Examples of Adverse Events that Represent Unanticipated Problems and Need to be Reported Under the HHS Regulations at 45 CFR Part 46

(1) A subject with chronic gastroesophageal reflux disease enrolls in a randomized, placebo-controlled, double-blind, phase 3 clinical trial evaluating a new investigational agent that blocks acid release in the stomach. Two weeks after being randomized and started on the study intervention the subject develops acute kidney failure as evidenced by an increase in serum creatinine from 1.0 mg/dl pre-randomization to 5.0 mg/dl. The known risk profile of the investigational agent does not include renal toxicity, and the IRB-approved protocol and informed consent document for the study does not identify kidney damage as a risk of the research. Evaluation of the subject reveals no other obvious cause for acute renal failure. The investigator concludes that the episode of acute renal failure probably was due to the investigational agent. This is an example of an unanticipated problem that must be reported because the subject’s acute renal failure was (a) unexpected in nature, (b) related to participation in the research, and (c) serious.

(2) A subject with seizures enrolls in a randomized, phase 3 clinical trial comparing a new investigational anti-seizure agent to a standard, FDA-approved anti-seizure medication. The subject is randomized to the group receiving the investigational agent. One month after enrollment, the subject is hospitalized with severe fatigue and on further evaluation is noted to have severe anemia (hematocrit decreased from 45% pre-randomization to 20%). Further hematologic evaluation suggests an immune-mediated hemolytic anemia. The known risk profile of the investigational agent does not include anemia, and the IRB-approved protocol and informed consent document for the study do not identify anemia as a risk of the research. The investigators determine that the hemolytic anemia is possibly due to the investigational agent. This is an example of an unanticipated problem that must be reported because the hematologic toxicity was (a) unexpected in nature; (b) possibly related to participation in the research; and (c) serious.

(3) The fifth subject enrolled in a phase 2, open-label, uncontrolled clinical study evaluating the safety and efficacy of a new oral agent administered daily for treatment of severe psoriasis unresponsive to FDA-approved treatments, develops severe hepatic failure complicated by encephalopathy one month after starting the oral agent. The known risk profile of the new oral agent prior to this event included mild elevation of serum liver enzymes in 10% of subjects receiving the agent during previous clinical studies, but there was no other history of subjects developing clinically significant liver disease. The IRB-approved protocol and informed consent document for the study identifies mild liver injury as a risk of the research. The investigators identify no other etiology for the liver failure in this subject and attribute it to the study agent. This is an example of an unanticipated problem that must be reported because although the risk of mild liver injury was foreseen, severe liver injury resulting in
hepatic failure was (a) unexpected in severity; (b) possibly related to participation in the research; and (c) serious.

(4) Subjects with coronary artery disease presenting with unstable angina are enrolled in a multicenter clinical trial evaluating the safety and efficacy of an investigational vascular stent. Based on prior studies in animals and humans, the investigators anticipate that up to 5% of subjects receiving the investigational stent will require emergency coronary artery bypass graft (CABG) surgery because of acute blockage of the stent that is unresponsive to non-surgical interventions. The risk of needing emergency CABG surgery is described in the IRB-approved protocol and informed consent document. After the first 20 subjects are enrolled in the study, a DSMB conducts an interim analysis, as required by the IRB-approved protocol, and notes that 10 subjects have needed to undergo emergency CABG surgery soon after placement of the investigational stent. The DSMB monitoring the clinical trial concludes that the rate at which subjects have needed to undergo CABG greatly exceeds the expected rate and communicates this information to the investigators. This is an example of an unanticipated problem that must be reported because (a) the frequency at which subjects have needed to undergo emergency CABG surgery was significantly higher than the expected frequency; (b) these events were related to participation in the research; and (c) these events were serious.

(5) Subjects with essential hypertension are enrolled in a phase 2, non-randomized clinical trial testing a new investigational antihypertensive drug. At the time the clinical trial is initiated, there is no documented evidence of gastroesophageal reflux disease (GERD) associated with the investigational drug, and the IRB-approved protocol and informed consent document do not describe GERD as a risk of the research. Three of the first ten subjects are noted by the investigator to have severe GERD symptoms that began within one week of starting the investigational drug and resolved a few days after the drug was discontinued. The investigator determines that the GERD symptoms were most likely caused by the investigational drug and warrant modification of the informed consent document to include a description of GERD as a risk of the research. This is an example of an adverse event that, although not serious, represents an unanticipated problem that must be reported because it was (a) unexpected in nature; (b) possibly related to participation in the research; and (c) suggested that the research placed subjects at a greater risk of physical harm than was previously known or recognized.

(6) A behavioral researcher conducts a study in college students that involves completion of a detailed survey asking questions about early childhood experiences. The research was judged to involve no more than minimal risk and was approved by the IRB chairperson under an expedited review procedure. During the completion of the survey, one student subject has a transient psychological reaction manifested by intense sadness and depressed mood that resolved without intervention after a few hours. The protocol and informed consent document for the research did not describe any risk of such negative psychological reactions.
Upon further evaluation, the investigator determines that the subject’s negative psychological reaction resulted from certain survey questions that triggered repressed memories of physical abuse as a child. The investigator had not expected that such reactions would be triggered by the survey questions. This is an example of an unanticipated problem that must be reported in the context of social and behavioral research because, although not serious, the adverse event was (a) unexpected; (b) related to participation in the research; and (c) suggested that the research places subjects at a greater risk of psychological harm than was previously known or recognized.

In all of these examples, the adverse events warranted consideration of substantive changes in the research protocol or informed consent process/document or other corrective actions in order to protect the safety, welfare, or rights of subjects.

NOTE: For purposes of illustration, the case examples provided above represent generally unambiguous examples of adverse events that are unanticipated problems. OHRP recognizes that it may be difficult to determine whether a particular adverse event is unexpected and whether it is related or possibly related to participation in the research.